許立松Li-Sung Hsu黃昱仁生化暨生物科技研究所2026-10-289999-12-312010https://handle.ncl.edu.tw/11296/avqx39https://scholars.csmu.edu.tw/handle/123456789/35622Osteosarcoma (OS)肉骨瘤,是種常見的惡性骨癌,每4-5百萬人之中就會被診斷患有此種疾病,而且大約60%的病人發病的年紀都小於25歲。目前對於肉體瘤的治療主要豆以手術切除和化療為主紫草素是從中國傳統草藥Lithospermum erythrorhizon (Sieb. et Zucc)、Arnebia euchroma (Royle, Johnst)或Arnebia guttata (Bunge)紫草屬(gromwell)之植物所莘取出來的,是種天然萘醌,具有抗發炎、抗癌、抗菌、抗黴及抗人類免疫缺陷病毒(anti-HIV)的特性。但是紫草素對於肉骨瘤細胞生長尚未被報導。本研究主要探討紫草素對於人類肉骨瘤細胞株143B之抗癌效果用,首先我們以MTT分析紫草素對於肉骨瘤細胞毒殺的效果,結果顯示隨著濃度增加以及處理時間增加,紫草素有明顯的抑制肉骨瘤細胞生長的現象。處理紫草素24或48小時,百分之五十致死濃度分別為4.55 and 2.01 μM。處理紫草素不僅會造成細胞型態的改變外,用DAPI染色後亦有核濃染的情形。經由propidium iodide (PI)染色及式細胞儀分析觀察,結果發現紫草素會引發細胞凋亡的情形產生。利用西方點墨法,結果我們發現紫草素可以經由活化ERK pathway,將ERK磷酸化,促使caspase 3與PARP的切割,Bcl-2蛋白的下降,引發細胞凋亡。利用DCFDA染色,可觀察到紫草素可使肉骨瘤細胞產生大量活性氧化分子(reactive oxygen species;ROS),前處理抗氧化劑N-acetyl-cysteine (NAC)不但能降低紫草素所造成ROS的產生並且能減少紫草素對肉骨瘤細胞的毒殺效果。綜合以上結果顯示紫草素可以作為一個新的治療肉骨瘤的藥物。Osteosarcoma (OS) is the most common primary malignant bone tumor, with an estimated incidence of 4–5 per million populations. It most frequently occurs in the second decade with some 60% of patients under the age of 25.1 Although the introduction of adjuvant chemotherapy in combination with surgical treatment has improved the long-term survival rate of OS patients. It still remains important to search for more effective and less toxic drug for treating OS. Shikonin, a natural naphthoquinone isolated from the traditional Chinese medicine (Lithospermum erythrorhizon), has been reported to possess tumor cell- killing activity , exhibits multiple biological functions including antimicrobial, anti-inflammatory, and anti-HIV effects. However, the effects of shikonin on cell growth of OS still remained to be elucidated. In this study, we delineated the molecular mechanisms of shikonin in the apoptosis of 143B osteosarcoma cells. Shikonin reduced the cell viability of 143B cells in a dose- and time-dependent manner. The IC50 at 24 h and 48 h for 143B cells was 4.55 and 2.01 μM, respectively. A significantly elicited hypodiploid cell population was found in cells treated with 2, 4, and 8 μM shikonin for 24 h. Moreover, treatment with shikonin induced reactive oxygen species (ROS) generation, increased extracellular signal-regulated kinase (ERK) phosphorylation, decreased B-cell lymphoma-2 (Bcl2) expression, and was accompanied by poly (ADP-ribose) polymerase (PARP) cleavage. Pretreatment with the antioxidant agent N-acetyl cysteine (NAC) not only reversed shikonin-induced ROS generation but also significantly attenuated the cytotoxic effects of shikonin in 143B cells. Furthermore, NAC attenuated shikonin-induced ERK phosphorylation. Taken together, our results revealed that shikonin increased ROS generation and ERK activation, and reduced Bcl2, which consequently caused the cells to undergo apoptosis. Therefore, shikonin may be a promising hemotherapeutic agent for osteosarcoma treatment.紫草素誘發肉骨瘤細胞走向細胞凋亡透過活性氧分子及細胞外訊息調控的激酶路徑thesis